Amplia COO discusses FAK inhibitor breakthrough in cancer trial - ASX SMIDcaps Conference

Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF) chief operating officer Dr Rhiannon Jones talked with Jonathan Jackson with Proactive at the ASX Small and Mid-Caps Conference about the company’s development of Focal Adhesion Kinase (FAK) inhibitors targeting fibrotic cancers, including pancreatic and ovarian cancer. Jones explained how Amplia’s lead drug works to reduce the fibrotic matrix surrounding tumours, improving the ability of chemotherapy to penetrate and act effectively. She noted that this approach is particularly relevant in difficult-to-treat cancers such as pancreatic cancer, where dense tissue can limit treatment success. Discussing results from the ongoing ACCENT clinical trial, Jones highlighted a significant milestone. Independent reviewers identified multiple complete responses, with tumours and metastases disappearing in several patients. As she stated: “There were five patients across both the part A and part B of the study that had a disappearance of the tumour and metastases.” She added that this compares favourably to historical data, where such outcomes are extremely rare. Jones emphasised that while curing pancreatic cancer remains challenging, progress is being made through combination therapies and continued research. She also outlined Amplia’s upcoming milestones, including further data releases, continued progression of pancreatic cancer trials, and potential expansion into ovarian cancer studies. The company is also presenting its latest findings at major international conferences, helping raise awareness among key opinion leaders and the broader oncology community. #AmpliaTherapeutics #PancreaticCancer #CancerResearch #BiotechStocks #FAKInhibitors #ClinicalTrials #Oncology #DrugDevelopment #CancerTreatment #HealthcareInnovation #SmallCapStocks #BiotechNews #OvarianCancer #MedicalResearch #ProactiveInvestors